Skip main navigation

N-Domain–Specific Substrate and C-Domain Inhibitors of Angiotensin-Converting Enzyme

Angiotensin-(1–7) and Keto-ACE
Originally publishedhttps://doi.org/10.1161/01.HYP.31.4.912Hypertension. 1998;31:912–917

    Abstract

    Abstract—We used the isolated N- and C-domains of the angiotensin I–converting enzyme (N-ACE and C-ACE; ACE; kininase II) to investigate the hydrolysis of the active 1–7 derivative of angiotensin (Ang) II and inhibition by 5-S-5-benzamido-4-oxo-6-phenylhexanoyl-l-proline (keto-ACE). Ang-(1–7) is both a substrate and an inhibitor; it is cleaved by N-ACE at approximately one half the rate of bradykinin but negligibly by C-ACE. It inhibits C-ACE, however, at an order of magnitude lower concentration than N-ACE; the IC50 of C-ACE with 100 μmol/L Ang I substrate was 1.2 μmol/L and the Ki was 0.13. While searching for a specific inhibitor of a single active site of ACE, we found that keto-ACE inhibited bradykinin and Ang I hydrolysis by C-ACE in approximately a 38- to 47-times lower concentration than by N-ACE; IC50 values with C-ACE were 0.5 and 0.04 μmol/L. Furthermore, we investigated how Ang-(1–7) acts via bradykinin and the involvement of its B2 receptor. Ang-(1–7) was ineffective directly on the human bradykinin B2 receptor transfected and expressed in Chinese hamster ovary cells. However, Ang-(1–7) potentiated arachidonic acid release by an ACE-resistant bradykinin analogue (1 μmol/L), acting on the B2 receptor when the cells were cotransfected with cDNAs of both B2 receptor and ACE and the proteins were expressed on the plasma membrane of Chinese hamster ovary cells. Thus like other ACE inhibitors, Ang-(1–7) can potentiate the actions of a ligand of the B2 receptor indirectly by binding to the active site of ACE and independent of blocking ligand hydrolysis. This potentiation of kinins at the receptor level can explain some of the well-documented kininlike actions of Ang-(1–7).

    Ang-(1–7) is an active metabolite released by peptidases from Ang I or II.1 Neutral endopeptidase 24.11 (neprilysin) cleaves the decapeptide Ang I to a tripeptide and to Ang-(1–7).2 Prolylendopeptidase and metalloendopeptidase 24.15 catalyze the same reaction.34 Ang II is converted by prolylcarboxypeptidase to a heptapeptide at its Pro7-Phe8 bond.5 The resulting heptapeptide is biologically active, but its actions differ from those of the parent peptide. It is not dipsogenic and does not stimulate aldosterone release. Instead of being a vasoconstrictor as Ang II is, it is a vasodilator on coronary arteries. In addition, the heptapeptide is antiproliferative and releases neurotransmitters and vasopressin.6789

    Although the existence of a receptor for Ang-(1–7) was reported,101112 many of its effects involve BK, and they cannot be explained by the presence of a specific receptor for the heptapeptide. Thus the vasodilator effect of Ang-(1–7) on porcine, canine, or human arterial strips was attributed to NO release, very likely mediated by BK.913 This vasodilation and hypotension by Ang-(1–7) were also abolished by the BK B2 receptor antagonist HOE 140.14 In addition, Ang-(1–7) inhibits purified canine ACE.9 It is hypothesized that Ang-(1–7) is synergistic with BK because it either has a different Ang receptor subtype, is a ligand for the B2 receptor, or inhibits the enzymatic inactivation of BK.9

    Ang I and BK are among the physiologically important substrates of Ang I–converting enzyme (kininase II; ACE); thus ACE inhibitors have dual actions in blocking hydrolysis of both peptides.15161718 The molecular cloning and sequencing of the complementary DNA for human and animal ACE revealed that ACE (somatic ACE) has two homologous domains,192021 each containing an active center. According to their position in the N-terminal half or in the C-terminal half of the single chain protein, they are designated N- or C-domain, which will be referred to here as N-ACE and C-ACE. The synthesis of ACE is directed by a single gene in the body. The testicular form of the enzyme (germinal ACE) is shorter than the somatic ACE (732 versus 1306 residues) and contains only the C-domain, which is attached to cell membranes1617202122232425 ; thus it lacks the N-domain active site.152021222324252627

    Because keto-ACE inhibited the hydrolysis of a tripeptide representing the C-terminus of Ang I at an order lower concentration than it inhibited hydrolysis of a tripeptide similar to the C-terminus of BK,28 it was tested to see whether it would be a relatively specific inhibitor for one of the active centers. We also report here that Ang-(1–7) is cleaved to Ang-(1–5) and His-Pro, mainly by N-ACE, as it is only very slowly hydrolyzed by C-ACE. As such, it is a more potent inhibitor of the C-domain active site than N-ACE. Although Ang-(1–7) is an inhibitor, it potentiates the effects of BK independent of blocking its metabolism. In this regard, it acts similarly to classic ACE inhibitors that induce “crosstalk” between the enzyme and the receptor.2930

    Methods

    Materials

    Hippuryl-glycyl-glycine (Hip-Gly-Gly), BK, angiotensin, and their metabolites, tissue culture medium, buffers, and reagents were purchased from Sigma Chemical Co. Phenyl-4-(n)-[3H]-hippuryl-glycyl-glycine ([3H]-Hip-Gly-Gly) and 5,6,8,9,11,12,14,15-[3H]-arachidonic acid ([3H]-AA) were purchased from Amersham and hippuryl-histidyl-leucine (Hip-His-Leu) from Bachem. The keto-ACE was a gift from Dr R.G. Ahlquist at the Stanford Research Institute (Stanford, Calif). CHO cells were obtained from the American Type Culture Collection. The more ACE-resistant BK derivative HT-BK was from Novabiochem. Fetal bovine serum (FBS) was from Atlanta Biologicals. The cDNAs of ACE and B2 receptor were kindly donated by Prof P. Corvol, College de France, and Dr K. Jarnigan, Syntex Co (Palo Alto, Calif). Enalaprilat was provided by Merck, Sharp & Dohme Research Division. Human recombinant ACE, expressed from a cDNA mutated to have only a functional C-domain active site (ACE K361, K365), was a gift of Dr Francois Alhenc-Gelas of INSERM U367, Paris.

    Enzyme Purification

    The N-ACE, C-ACE, and somatic ACE were purified as described.31 N-ACE was purified from ileal fluid collected after colostomy with the collaboration of N. Davidson of the University of Chicago, somatic ACE from human cadaver kidneys, and C-ACE from rabbit testicles obtained from Pel-Freez Co. Approval for human tissue studies was granted by the Institutional Review Board at the University of Chicago and for animal tissue study by the Animal Care and Usage Committee at the University of Illinois at Chicago.

    Protein Assay

    The protein concentration of purified enzymes was determined as before.32

    Enzyme Assays

    ACE activity was determined by several techniques. In a recording spectrophotometric assay, Hip-His-Leu was the substrate. In a fluorometric assay, the dipeptide cleaved from this substrate was coupled to o-phthalic dicarboxaldehyde.33 A radiometric assay used [3H]Hip-Gly-Gly. The cleavage of longer peptide substrates was assessed by high-pressure liquid chromatography (HPLC).32

    Analysis of Hydrolysis Products

    The hydrolysis of the various peptides by the ACE enzymes was assayed by HPLC. After incubation of enzymes with a peptide, ice-cold 5% trifluoroacetic acid (TFA) was added to 1.7% final concentration to stop the reaction. Peptides and their hydrolysis products were separated on a Waters μBondapak C18 reverse-phase column with an increasing (5% to 40%) linear gradient of acetonitrile/0.05% TFA in H2O/0.05% TFA and detected with a Waters 484 detector at a wavelength of 214 nm.32 It was established that cleavage of the substrates followed zero-order kinetics to the time point of the assay.

    Hydrolysis of Peptides

    The rates of hydrolysis of the BK and angiotensin peptides were generally determined at 37°C in 50 mmol/L Tris-maleate buffer, pH 7.4, containing 150 mmol/L NaCl, 100 μmol/L substrate, and 2 nmol/L enzyme. The effect of chloride concentration was assessed in the same buffer containing from 0 to 150 mmol/L NaCl. The kinetics of Ang-(1–7) hydrolysis were established by incubating a 2-nmol/L concentration of either N-ACE, somatic ACE, or a 300-nmol/L concentration of C-ACE with the peptide in five different concentrations varying from 10 to 200 μmol/L in 50 mmol/L Tris-maleate, pH 7.4, and 150 mmol/L NaCl at 37°C. The amount of Ang-(1–5) formed was calculated from the peak area by comparison to a known standard. Kinetic parameters were calculated from Lineweaver-Burk plots.

    Inhibition Studies

    The effects of both keto-ACE and Ang-(1–7) on the hydrolysis of various substrates by N-ACE or C-ACE were determined by preincubating the enzyme for 30 minutes at 4°C with the potential inhibitor before addition of the substrate. A range of inhibitor concentrations was used and IC50 was calculated from the inhibition curve. The Ki was then calculated with kinetic parameters determined for uninhibited enzymes, with the following equation34 :

    Transfection of CHO Cells and Expression of ACE and B2 Receptor

    Construction

    An EcoRI fragment of B2 receptor cDNA (177 to 1770 bp) containing the whole coding region was cloned into the EcoRI site of pcDNA1. The direction of the insert was determined by restriction enzyme digestion and sequencing. A 4-kb EcoRI fragment of human ACE cDNA was also cloned into the EcoRI site of pcDNA3, and its direction was determined by restriction enzyme digestion.

    Transfection

    Human ACE-pcDNA3, BK B2 receptor–pcDNA1, and pHβAPr-3p-neo containing plasmids were used to transfect CHO cells with Lipofectin Reagent (Gibco BRL) as reported by us.29 Cell monolayers (approximately 50% confluent in 60- or 100-mm diameter dishes) were washed three times with serum-free Ham’s F-12. Lipofectin (30 to 80 μL) and DNA (5 to 15 μg/μL) were first individually diluted to 200 μL and then mixed together and incubated at room temperature for 15 minutes. An aliquot of the mixture (200 μL) was then diluted to 2 or 4 mL in serum-free Ham’s F-12 and applied to the cell culture monolayers. After 24 hours, the cells were washed twice and fed 5 or 10 mL of media containing 10% FBS. Two days later, the monolayers were subcultured after being treated with 0.5 mL trypsin/EDTA (0.025% trypsin/0.1 mmol/L EDTA) and plated at low density in media containing 10% FBS and 600 μg/mL geneticin. Clonal colonies that grew in the presence of the selection medium were isolated with glass cloning rings, fed every 48 to 72 hours, and subcultured as needed. Cells that expressed B2 receptor only were designated as CHO-3B cells. Cotransfected cells expressing both active ACE and B2 receptor were the CHO-15AB cells.29

    Effect of Ang-(1–7) on Arachidonic Acid Release by HT-BK

    Cells were grown on six-well plates in Ham’s F-12 medium containing 10% FBS. After reaching 60% to 80% confluence, the culture medium was replaced with Ham’s F-12 medium containing 0.5% FBS and 1 μCi/mL of [3H] arachidonic acid (loading medium). Cells were incubated in this medium for 24 hours. Monolayers were then washed three times with the release buffer (RB) (25 mmol/L HEPES, 150 mmol/L NaCl, 5 mmol/L KCl, 5.5 mmol/L dextrose, 0.8 mmol/L MgSO4, 1 mmol/L CaCl2, and 0.1% fatty acid-free BSA, pH 7.4). Triplicate wells were then incubated at 37°C for 30 minutes with one of the following treatments: (1) 1 mL of RB alone to measure basal [3H] arachidonic acid release (this value was later subtracted from each triplicate); (2) 1 μmol/L HT-BK in 1 mL RB; (3) 1 μmol/L HT-BK plus 1 μmol/L of Ang-(1–7) in 1 mL of RB; (4) 1 μmol/L HT-BK plus 10 μmol/L of Ang-(1–7) in 1 mL RB; (5) 1 μmol/L HT-BK plus 10 μmol/L of Ang II in 1 mL RB; or (6) 10 μmol/L of Ang-(1–7) in 1 mL of RB without added HT-BK. After this time period, RB from each well was simply transferred to scintillation vials (released [3H] arachidonic acid is bound to fatty acid–free BSA and counted).29

    Results

    Hydrolysis of Ang-(1–7) and BK by N-ACE and C-ACE

    The decrease in the amount of unhydrolyzed substrate and the increase in hydrolysis products [Ang-(1–5), BK-(1–7), and BK-(1–5)] were determined by comparison of the peak areas with peak areas of known standard peptides31 in HPLC.

    The results of the hydrolysis of Ang-(1–7) and BK by N-ACE and C-ACE are given in Table 1. Note that whereas BK was hydrolyzed approximately equally by both N-ACE and C-ACE under the conditions used (2 nmol/L enzyme, 100 μmol/L substrate, Cl 150 mmol/L), the amount of Ang-(1–7) cleaved by the two enzymes differed greatly. N-ACE hydrolyzed Ang-(1–7) at about one half of the rate at which it hydrolyzed BK, whereas C-ACE in the concentration used did not cleave Ang-(1–7). These results are taken to show that Ang-(1–7) is primarily a substrate of the N-domain active site of ACE.

    Effect of Cl Concentration on Ang-(1–7) Hydrolysis

    To determine this, the substrate was exposed to the enzymes at Cl concentrations ranging from 0 to 300 mmol/L. The hydrolysis of Ang-(1–7) by N-ACE was stimulated less than twofold when the Cl concentration was raised to 300 mmol/L from 0. (Because the N-ACE was not dialyzed, the activity at 0 Cl may in fact be due to a trace of Cl present.) There was still no detectable hydrolysis of Ang-(1–7) by C-ACE at any chloride concentration used.

    Kinetics of Ang-(1–7) Hydrolysis

    Because Ang-(1–7) was not hydrolyzed when the peptide was incubated with 2 nmol/L C-ACE for up to 3 hours, a much higher concentration of the enzyme was tried. Measurable activity was obtained when 100 μmol/L Ang-(1–7) was incubated with 300 nmol/L C-ACE for 3 hours. The product was Ang-(1–5), and the reaction was completely blocked by 1 μmol/L enalaprilat, indicating that the hydrolysis was due to ACE (data not shown). Therefore, the kinetics of hydrolysis of Ang-(1–7) were determined with 300 nmol/L C-ACE, 2 nmol/L N-ACE, and 2 nmol/L somatic ACE with various substrate concentrations (Table 2). The Km of Ang-(1–7) with the three representative forms of ACE was 4.3, 6.8, and 6.6 μmol/L for N-ACE, C-ACE, and somatic ACE, respectively. The kcat value for N-ACE (27 min−1) was 75 times higher than the kcat for C-ACE (0.36 min−1) and quite similar to the kcat for somatic ACE (23.7 min−1). These values yield a specificity constant (kcat/Km) for N-ACE (6.1) that is 100 times larger than that for C-ACE (0.06) and 1.6 times greater than that for somatic ACE (3.7).

    Ang-(1–7) was incubated with another source of C-ACE, somatic ACE,2324 where His in positions 361 and 365 was mutated to Lys, thereby rendering the N-ACE domain inactive. Ang-(1–7) in these experiments was not hydrolyzed by the C-ACE (10 nmol/L), although the enzyme cleaved Hip-His-Leu (data not shown). Higher concentration of enzyme was not tried because of the limited amount of available material.

    Inhibition of C-ACE and N-ACE by Ang-(1–7)

    The low Km with both active sites (lower than that of Ang I)21 and the very low kcat of Ang-(1–7) with C-ACE indicated that Ang-(1–7) may be an inhibitor of the enzyme. This idea was tested by determining the IC50 values and Ki of Ang-(1–7) with Hip-His-Leu, Ang I, and BK as substrates of C-ACE and N-ACE. Table 3 shows that Ang-(1–7) inhibited C-ACE in μmol/L concentrations. The IC50 values of Ang-(1–7) with Ang I, BK, and Hip-His-Leu hydrolysis were 1.2, 3.9, and 8.2 μmol/L, respectively. With N-ACE, the IC50 values were 9 to 23 times higher (28, 46, and 71 μmol/L for inhibition of Ang I, BK, and Hip-His-Leu hydrolysis, respectively). The Ki values are also indicated in Table 3.

    Inhibition of ACE by Keto-ACE

    The reported pattern of keto-ACE inhibition of hydrolysis of various substrates by somatic ACE28 indicated that it may be a relatively specific inhibitor for one of the ACE active sites. We therefore studied the inhibition of the hydrolysis of BK and Ang I by both N-ACE and C-ACE. Table 4 shows that keto-ACE is indeed relatively actively site-specific. With equal concentrations of N-ACE and C-ACE, the IC50 of keto-ACE was 47 times lower for C-ACE (0.51 μmol/L) than for N-ACE (24 μmol/L) with BK as the substrate. When Ang I was the substrate, the IC50 was 38 times lower for C-ACE (0.04 μmol/L) than for N-ACE (1.5 μmol/L). Thus keto-ACE is a more potent inhibitor of the C-domain active site of ACE.

    Effect of Ang-(1–7) on BK-Induced Arachidonic Acid Release From Transfected CHO Cells

    We reported that ACE inhibitors potentiate the effect of BK and analogues on B2 receptors, and this potentiation in the systems used is not due to inhibition of BK hydrolysis by ACE.2930 Therefore we tested the effect of Ang-(1–7) on the response of CHO cells grown in culture and transfected to express both ACE and B2 receptor (CHO-15AB cells) or B2 receptor only (CHO-3B). As ligand, the BK analogue HT-BK,2930 which is more resistant to hydrolysis by ACE than BK, was used (Figure). Arachidonic acid released in response to HT-BK in the absence or presence of Ang-(1–7) was measured. Values were normalized to the amount of arachidonic acid released by HT-BK stimulation alone. The addition of either 1 μmol/L or 10 μmol/L of Ang-(1–7) to CHO-15AB cells increased the arachidonic acid release by HT-BK approximately twofold or threefold but only from cells that contained both ACE and B2 receptor (CHO-15AB) (Figure). There was no significant increase over the baseline unstimulated value when Ang-(1–7) without HT-BK was added to the cells, and the unmetabolized octapeptide Ang II did not potentiate HT-BK. When the experiments were repeated with cells that were transfected with B2 receptor only (CHO-3B cells29 ), Ang-(1–7) was inactive and did not augment ligand activity on the B2 receptor (Figure); the release of arachidonic acid by 1 μmol/L HT-BK in the presence or absence of 10 μmol/L Ang-(1–7) was not different. Thus similar to other ACE inhibitors,2930 Ang-(1–7) potentiation of kinin action on the B2 receptor requires the coexpression of ACE in the cells and goes beyond inhibition of the enzymatic breakdown of the B2 receptor agonists.

    Discussion

    We report here that Ang-(1–7) potentiates BK activity on its B2 receptor. However, Ang-(1–7) does not act directly on the B2 receptor, since it was inactive in CHO-3B cells expressing the receptor but no ACE. Ang-(1–7) stimulated arachidonic acid release by the ligand of the B2 receptor in CHO-15AB cells when both human ACE and B2 receptor were coexpressed, and this effect was not due to inhibition of BK inactivation. The parent peptide Ang II was inactive, since it is neither a substrate or inhibitor of ACE, possibly because its C-terminus is Pro7-Phe8 and not Pro7 as in Ang-(1–7). C-terminal proline is an important component of ACE inhibitors for interaction with the enzyme.1617

    In isolated heart tissue,30 guinea pig ileum (R.D. Minshall, S.F. Rabito, R. Igic, E.G. Erdös, unpublished observations, 1997), or cultured cells cotransfected with B2 receptor and ACE,29 the activation of B2 receptor by ACE inhibitors was not primarily due to blocking kinin breakdown because ACE-resistant B2 ligands were also potentiated. Addition of an active ACE inhibitor immediately enhanced BK activity as much as severalfold on all preparations tested.2930 This immediate response cannot be correlated with the much slower hydrolysis of kinins in the same preparations. Ang-(1–7) acted similarly to other ACE inhibitors, demonstrated in more extensive studies.2930 In these investigations,29 ACE inhibitors enhanced the number of BK binding sites, protected high-affinity sites, abolished the desensitization of the receptor, and delayed endocytosis. That Ang-(1–7) inhibits ACE was also shown by others.9 However, the inhibition, because of the differences in activity of the two domains, is more complex. Ang-(1–7) is a substrate of N-ACE but it also inhibits N-ACE, although at higher concentration than C-ACE. C-ACE cleaves Ang-(1–7) approximately 100 times slower than N-ACE, but Ang-(1–7) inhibits it at an order of magnitude lower concentration.

    In ACE, the active site on the N-domain may more readily be exposed to bloodborne substrates and inhibitors; the enzyme is inserted into the plasma membrane by a transmembrane anchor peptide of the C-domain.15222324253536 ACE inhibitors bind to both active sites, but depending on their structure, they may differ in their affinities, primarily because of differences in dissociation rates from the two active sites.323738 We discovered in human ileal fluid collected after surgery a naturally occurring, short form of ACE having only the N-domain active site; the molecular mass of this deglycosylated ACE is 68 kD. This enzyme was the source of N-ACE in these experiments. For C-ACE, we used rabbit testicular ACE, which has 87% identity with the human C-domain. In the regions containing the active residues (426–469 rabbit, 989–1032 human somatic ACE), the identity is 100%.2324 Nevertheless, we carried out control experiments with mutant recombinant human somatic ACE in which only the C-domain was functional (not shown) because two His residues were mutated to Lys.2324 The results were similar to those obtained with rabbit testicular ACE, and this human C-ACE also did not cleave Ang-(1–7).

    It appears that vasodilation and probably NO release by Ang-(1–7)91314 can be due to indirect potentiation of BK as an agonist of the B2 receptor. This explains why Ang II receptor blockers were inactive, but a B2 receptor blocker abolished Ang-(1–7) effects.914 It also follows that ACE inhibitors may block some of the activity of Ang-(1–7) by similar effects and competing for ACE.92930

    Because of the differences in the cleavage of biological substrates by the two domains, it would be important to develop a second generation of ACE inhibitors that react mainly with one of the active sites of ACE.3940 Ang-(1–7) appears to be a relatively specific substrate of N-ACE but an inhibitor of C-ACE. The other inhibitor we used, keto-ACE, also inhibits C-ACE at much lower concentration than N-ACE. Keto-ACE is a ketomethylene derivative of a blocked tripeptide substrate, Bz-Phe-Gly-Pro.41 The IC50 for N-ACE was 38 to 47 times higher than for C-ACE with Ang I and BK substrates. The reported inhibition of short substrates2842by keto-ACE can be interpreted now as caused by the different affinities of substrates and inhibitors for the two active sites.

    In conclusion, we have shown that Ang-(1–7) is both a substrate and an inhibitor of ACE. Some of its pharmacological effects may be attributed to an indirect potentiation of BK action on its B2 receptor by binding to the active site of ACE. This potentiation is not due primarily to inhibition of BK inactivation by ACE but to an induction of “crosstalk” between B2 receptor and ACE on plasma membranes, which is triggered by ACE inhibitors.29

    Selected Abbreviations and Acronyms

    ACE=angiotensin-converting enzyme
    Ang=angiotensin
    BK=bradykinin
    CHO=Chinese hamster ovary (cells)
    HT-BK=more ACE-resistant BK derivative [hydroxyproline3,methyltyrosine8]-BK
    keto-ACE=5-S-5-benzamido-4-oxo-6-phenylhexanoyl-l-proline

    Presented in part at the 51st Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, American Heart Association, Washington, DC, September 16–19, 1997; and published in abstract form (Hypertension. 1997;30;494.).

    
          Figure 1.

    Figure 1. Top, Ang-(1–7) potentiates the release of arachidonic acid (AA) by HT-bradykinin (HT-BK) from CHO cells transfected both with ACE and B2 receptor (CHO-15AB). Bottom, Ang-(1–7) is inactive if only B2 receptor is transfected and expressed (CHO-3B). Cells were stimulated by 1 μmol/L HT-BK alone (open bar), HT-BK+1 μmol/L Ang-(1–7) (diagonally lined bar), HT-BK+10 μmol/L Ang-(1–7) (cross-hatched bar), HT-BK+10 μmol/L Ang II (vertically lined bar); and 10 μmol/L Ang-(1–7) (filled bar). Ang II did not potentiate the effect of HT-BK, and Ang-(1–7) without added B2-agonist was inactive. Values are mean±SEM, *P<.05. Ordinate equals the relative release of labeled AA, with release by HT-BK alone taken as 1.

    Table 1. Hydrolysis of Ang-(1-7) and BK by N-ACE and C-ACE

    Enzyme1Substrate Hydrolyzed, nmol2
    Ang-(1-7)BK
    N-ACE1.9 ±0.33.6±0.8
    C-ACE04.2 ±0.6

    1Enzyme concentration, 2 nmol/L.

    2Enzyme incubated with 100 μmol/L substrate for 1 hour at 37°C; all values expressed as mean±SEM (n=3).

    Table 2. Kinetic Parameters for Hydrolysis of Ang-(1-7)

    EnzymeKm, μmol/Lkcat, min−1kcat/Km
    N-ACE, 2 nmol/L4.3±0.4127 ±3.56.1±0.2
    C-ACE, 300 nmol/L6.8±1.10.36 ±0.0220.06±0.013
    Somatic ACE, 2 nmol/L6.6 ±0.823.7±1.33.7±0.9

    n=3 for each enzyme. All values are expressed as mean±SEM.

    1P>.1, no significant differences.

    2P<.001 between C-ACE and either N-ACE or somatic ACE.

    3P<.01 between C-ACE and either N-ACE or somatic ACE.

    Table 3. Inhibition of C-ACE and N-ACE by Ang-(1-7)

    Substrate, ConcentrationIC50 and Ki Ang-(1-7), μmol/L
    C-ACE1N-ACE2
    IC50KiIC50Ki
    Hip-His-Leu, 1 mmol/L8.2 ±1.20.16±0.0371 (68–74)4.2 (4.0–4.4)
    Ang I, 100 μmol/L1.2±0.40.13 ±0.0528 (22–33)3.4 (2.7–4.1)
    BK, 10 μmol/L3.9±0.60.05±0.0146 (43–48)1.7 (1.6–1.8)

    Enzyme concentration, 2 nmol/L.

    1Expressed as mean±SEM; n=3 for each substrate.

    2Values are the average (and range) of two experiments.

    Table 4. Inhibition of Hydrolysis of BK and Ang I by Keto-ACE

    Substrate1Keto-ACE IC502
    N-ACE, μmol/LC-ACE, μmol/L
    BK24±50.51±0.4
    Ang I1.5 ±0.30.04±.005

    1Substrate concentration, 100 μmol/L.

    2Enzyme concentration, 2 nmol/L. All values expressed as mean±SEM (n=3).

    These studies were supported in part by MERIT grant HL-36473 from the National Heart, Lung, and Blood Institute, National Institutes of Health. We thank Richard D. Minshall, PhD, and William Campbell, PhD, for helpful discussions; Dr Bernhard A. Schölkens for a gift of HOE-140; and Sara Thorburn, MA, for editorial assistance.

    Footnotes

    Correspondence to Ervin G. Erdös, MD, University of Illinois College of Medicine at Chicago, Department of Pharmacology (M/C 868), 835 S Wolcott Ave, Chicago, IL 60612-7344. E-mail

    References

    • 1 Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci.1993; 52:1461–1480.CrossrefMedlineGoogle Scholar
    • 2 Gafford JT, Skidgel RA, Erdös EG, Hersh LB. Human kidney “enkephalinase,” a neutral metalloendopeptidase that cleaves active peptides. Biochemistry.1983; 22:3265–3271.CrossrefMedlineGoogle Scholar
    • 3 Chappell MC, Tallant EA, Brosnihan KB, Ferrario CM. Conversion of angiotensin I to angiotensin-(1–7) by thimet oligopeptidase (EC 3.4.24.15) in vascular smooth muscle cells. J Vasc Med Biol.1994; 5:129–137.Google Scholar
    • 4 Santos RAS, Brosnihan KB, Jacobsen DW, DiCorleto PE, Ferrario CM. Production of angiotensin-(1–7) by human vascular endothelium. Hypertension. 1992;19(suppl II):II-56–II-61.Google Scholar
    • 5 Tan F, Morris PW, Skidgel RA, Erdös EG. Sequencing and cloning of human prolylcarboxypeptidase (angiotensinase C): similarity to both serine carboxypeptidase and prolylendopeptidase families. J Biol Chem.1993; 268:16631–16638.CrossrefMedlineGoogle Scholar
    • 6 Ferrario CM, Barnes KL, Block CH, Brosnihan KB, Diz DI, Khosla MC, Santos RAS. Pathways of angiotensin formation and function in the brain. Hypertension. 1990;15(suppl I):I-13–I-19.Google Scholar
    • 7 Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1–7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996;27(part 2):523–528.Google Scholar
    • 8 Schiavone MT, Santos RAS, Brosnihan KB, Khosla MC, Ferrario CM. Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1–7) heptapeptide. Proc Natl Acad Sci U S A.1988; 85:4095–4098.CrossrefMedlineGoogle Scholar
    • 9 Li P, Chappell MC, Ferrario CM, Brosnihan KB. Angiotensin-(1–7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension. 1997;29(part 2):394–400.Google Scholar
    • 10 Fontes MAP, Silva LCS, Campagnole-Santos MJ, Khosla MC, Guertzenstein PG, Santos RAS. Evidence that angiotensin-(1–7) plays a role in the central control of blood pressure at the ventro-lateral medulla acting through specific receptors. Brain Res.1994; 665:175–180.CrossrefMedlineGoogle Scholar
    • 11 Diz DI, Pirro NT. Differential actions of angiotensin II and angiotensin-(1–7) on transmitter release. Hypertension. 1992;19(suppl II):II-41–II-48.Google Scholar
    • 12 Tallant EA, Lu X, Weiss RB, Chappell MC, Ferrario CM. Bovine aortic endothelial cells contain an angiotensin-(1–7) receptor. Hypertension. 1997;29(part 2):388–393.Google Scholar
    • 13 Pörsti I, Bara AT, Busse R, Hecker M. Release of nitric oxide by angiotensin-(1–7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol.1994; 111:652–654.CrossrefMedlineGoogle Scholar
    • 14 Abbas A, Gorelik G, Carbini LA, Scicli AG. Angiotensin-(1–7) induces bradykinin-mediated hypotensive responses in anesthetized rats. Hypertension. 1997;30(part 1):217–221.Google Scholar
    • 15 Skidgel RA, Erdös EG. Biochemistry of angiotensin converting enzyme. In: Robertson JIS, Nicholls MG, eds. The Renin Angiotensin System. London, England: Gower Medical Publishing; 1993:10.1–10.10.Google Scholar
    • 16 Ondetti MA. From peptides to peptidases: a chronicle of drug discovery. Ann Rev Pharmacol.1994; 34:1–16.CrossrefGoogle Scholar
    • 17 Patchett AA, Cordes EH. The design and properties of N-carboxyalkyldipeptide inhibitors of angiotensin converting enzyme. Adv Enzymol Relat Areas Mol Biol.1985; 57:1–84.MedlineGoogle Scholar
    • 18 Gavras H. Angiotensin converting enzyme inhibition and the heart. Hypertension.1994; 23:813–818.LinkGoogle Scholar
    • 19 Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, Gregear G, Corvol P. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci U S A.1988; 85:9386–9390.CrossrefMedlineGoogle Scholar
    • 20 Bernstein KE, Martin BM, Edwards AS, Bernstein EA. Mouse angiotensin-converting enzyme is a protein composed of two homologous domains. J Biol Chem.1989; 264:11945–11951.CrossrefMedlineGoogle Scholar
    • 21 Wei L, Alhenc-Gelas F, Corvol P, Clauser E. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem.1991; 266:9002–9008.CrossrefMedlineGoogle Scholar
    • 22 Erdös EG, Gafford JT. Human converting enzyme. Clin Exp Hypertens. 1983;A5:1251–1262.Google Scholar
    • 23 Soubrier F, Hubert C, Testut P, Nadaud S, Alhenc-Gelas F, Corvol P. Molecular biology of the angiotensin I converting enzyme, I: biochemistry and structure of the gene. J Hypertens.1993; 11:471–476.CrossrefMedlineGoogle Scholar
    • 24 Soubrier F, Wei L, Hubert C, Clauser E, Alhenc-Gelas F, Corvol P. Molecular biology of the angiotensin I converting enzyme, II: structure-function: gene polymorphism and clinical implications. J Hypertens.1993; 11:599–604.CrossrefMedlineGoogle Scholar
    • 25 Kumar RS, Kusari J, Roy SN, Soffer RL, Sen GC. Structure of testicular angiotensin-converting enzyme: a segmental mosaic enzyme. J Biol Chem.1989; 264:16754–16758.CrossrefMedlineGoogle Scholar
    • 26 Kumar RS, Thekkumkara TJ, Sen GC. The mRNAs encoding the two angiotensin converting isozymes are transcribed from the same gene by a tissue-specific choice of alternative transcription initiation sites. J Biol Chem.1991; 266:3854–3862.CrossrefMedlineGoogle Scholar
    • 27 Ehlers MRW, Fox EA, Strydom DJ, Riordan JF. Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme. Proc Natl Acad Sci U S A.1989; 86:7741–7745.CrossrefMedlineGoogle Scholar
    • 28 Weare JA, Stewart TA, Gafford JT, Erdös EG. Inhibition of human converting enzyme in vitro by a novel tripeptide analog. Hypertension. 1981;3(suppl I):I-50–I-53.Google Scholar
    • 29 Minshall RD, Tan F, Nakamura F, Rabito SF, Becker RP, Marcic B, Erdös EG. Potentiation of the actions of bradykinin by angiotensin I converting enzyme (ACE) inhibitors: the role of expressed human bradykinin B2 receptors and ACE in CHO cells. Circ Res.1997; 81:848–856.CrossrefMedlineGoogle Scholar
    • 30 Minshall RD, Erdös EG, Vogel SM. Angiotensin I converting enzyme inhibitors potentiate bradykinin’s inotropic effects independently of blocking its inactivation. Am J Cardiol.1997; 80:132–136.CrossrefMedlineGoogle Scholar
    • 31 Deddish PA, Wang J, Michel B, Morris PW, Davidson NO, Skidgel RA, Erdös EG. Naturally occurring active N-domain of human angiotensin I converting enzyme. Proc Natl Acad Sci U S A.1994; 91:7807–7811.CrossrefMedlineGoogle Scholar
    • 32 Deddish PA, Wang L-X, Jackman HL, Michel B, Wang J, Skidgel RA, Erdös EG. Single-domain angiotensin I converting enzyme (kininase II): characterization and properties. J Pharmacol Exp Ther.1996; 279:1582–1589.MedlineGoogle Scholar
    • 33 Danilov S, Jaspard E, Churakova T, Towbin H, Savoie F, Wei L, Alhenc-Gelas F. Structure-function analysis of angiotensin I-converting enzyme using monoclonal antibodies: selective inhibition of the amino-terminal active sites. J Biol Chem.1994; 269:26806–26814.CrossrefMedlineGoogle Scholar
    • 34 Dixon M, Webb EC. Enzyme inhibition and activation. In: Enzymes. 3rd ed. New York, NY: Academic Press, Inc; 1979:334.Google Scholar
    • 35 Ramchandran R, Sen GC, Misono K, Sen I. Regulated cleavage-secretion of the membrane-bound angiotensin converting enzyme. J Biol Chem.1994; 269:2125–2130.CrossrefMedlineGoogle Scholar
    • 36 Lattion A-L, Soubrier F, Allegrini J, Hubert C, Corvol P, Alhenc-Gelas F. The testicular transcript of the angiotensin I-converting enzyme encodes for the ancestral, non-duplicated form of the enzyme. FEBS Lett.1989; 252:99–104.CrossrefMedlineGoogle Scholar
    • 37 Wei L, Clauser E, Alhenc-Gelas F, Corvol P. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem.1992; 267:13398–13405.CrossrefMedlineGoogle Scholar
    • 38 Perich RB, Jackson B, Johnston CI. Structural constraints of inhibitors for binding at two active sites on somatic angiotensin converting enzyme. Eur J Pharmacol.1994; 266:201–211.CrossrefMedlineGoogle Scholar
    • 39 Azizi M, Rousseau A, Ezan E, Guyene T-T, Michelet S, Grognet J-M, Lenfant M, Corvol P, Menard J. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem-cell regulator N-Acetyl-Seryl-Aspartyl-Lysyl-Proline. J Clin Invest.1996; 97:839–844.CrossrefMedlineGoogle Scholar
    • 40 Erdös EG. News about ACE, or, the separate lives of “Siamese Twin” domains. J Clin Invest.1996; 97:588.CrossrefMedlineGoogle Scholar
    • 41 Almquist RG, Chao W-R, Ellis ME, Johnson HL. Synthesis and biological activity of a ketomethylene analogue of a tripeptide inhibitor of angiotensin converting enzyme. J Med Chem.1980; 23:1392–1398.CrossrefMedlineGoogle Scholar
    • 42 Brooks RR, Miller KE, Jones SM, Burns RH, Huang C-T. Selectivity of converting-enzyme inhibitors for angiotensin I versus bradykinin hydrolysis reactions. J Pharm Sci.1990; 79:384–388.CrossrefMedlineGoogle Scholar

    eLetters(0)

    eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.

    Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.